EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC 4.0

Preclinical efficacy profiles of the sigma‐1 modulator E1R and of fenfluramine in two chronic mouse epilepsy models

Daniel Pérez-Pérez iD, Cristina Monío-Baca, Eva-Lotta von Rüden, Verena Buchecker, Amelie Wagner, Katharina Schönhoff, Liga Zvejniece, Dennis Klimpel, Heidrun Potschka iD

Epilepsia · 2024

DOI: 10.1111/epi.18037 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Epilepsia, 2024. Verfasst von Daniel Pérez-Pérez und 8 weiteren Autor:innen. Beteiligte Einrichtung: Institute of Pharmacology, Toxicology, and Pharmacy, Ludwig-Maximilians-Universität München, Munich, Germany. Hauptthemen laut MEDLINE: Receptors, sigma, Disease Models, Animal, Sigma-1 Receptor, Kindling, Neurologic. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 47 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: Deutsche Forschungsgemeinschaft.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Objective

Given its key homeostatic role affecting mitochondria, ionotropic and metabotropic receptors, and voltage‐gated ion channels, sigma‐1 receptor (Sig1R) represents an interesting target for epilepsy management. Antiseizure effects of the positive allosteric modulator E1R have already been reported in acute seizure models. Although modulation of serotonergic neurotransmission is considered the main mechanism of action of fenfluramine, its interaction with Sig1R may be of additional relevance.

Methods

To further explore the potential of Sig1R as a target, we assessed the efficacy and tolerability of E1R and fenfluramine in two chronic mouse models, including an amygdala kindling paradigm and the intrahippocampal kainate model. The relative contribution of the interaction with Sig1R was analyzed using combination experiments with the Sig1R antagonist NE‐100.

Results

Whereas E1R exerted pronounced dose‐dependent antiseizure effects at well‐tolerated doses in fully kindled mice, only limited effects were observed in response to fenfluramine, without a clear dose dependency. In the intrahippocampal kainate model, E1R failed to influence electrographic seizure activity. In contrast, fenfluramine significantly reduced the frequency of electrographic seizure events and their cumulative duration. Pretreatment with NE‐100 reduced the effects of E1R and fenfluramine in the kindling model. Surprisingly, pre‐exposure to NE‐100 in the intrahippocampal kainate model rather enhanced and prolonged fenfluramine's antiseizure effects. Significance In conclusion, the kindling data further support Sig1R as an interesting target for novel antiseizure medications. However, it is necessary to further explore the preclinical profile of E1R in chronic epilepsy models with spontaneous seizures. Despite the rather limited effects in the kindling paradigm, the findings from the intrahippocampal kainate model suggest that it is of interest to further assess a possible broad‐spectrum potential of fenfluramine.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Receptors, sigmaDisease Models, AnimalSigma-1 ReceptorKindling, NeurologicFenfluramineEpilepsyAnimalsMiceMaleAnticonvulsantsDose-Response Relationship, DrugPiperazinesAmygdalaHippocampusChronic DiseaseKainic AcidMice, Inbred C57BL

Stichwörter der Autor:innen

E1RNE‐100amygdala kindling modelantiseizure medicationfenfluramineintrahippocampal kainate model

Substanzen

Receptors, sigmaSigma-1 ReceptorFenfluramineAnticonvulsantsPiperazinesKainic Acid

Autor:innen und Institutionen

  • Institute of Pharmacology, Toxicology, and Pharmacy, Ludwig-Maximilians-Universität München, Munich, Germany.
  • Laboratory of Pharmaceutical Pharmacology, Latvian Institute of Organic Synthesis, Riga, Latvia.
  • Department of Forensic and Clinical Toxicology, Medizinisches Versorgungszentrum Labor Krone, Bad Salzuflen, Germany.

ORCID-Profile: Daniel Pérez-Pérez, Heidrun Potschka

Förderung

  • Deutsche Forschungsgemeinschaft

Zitieren

APA

Pérez-Pérez, D., Monío-Baca, C., von Rüden, E. L., Buchecker, V., Wagner, A., Schönhoff, K., Zvejniece, L., Klimpel, D., & Potschka, H. (2024). Preclinical efficacy profiles of the sigma‐1 modulator E1R and of fenfluramine in two chronic mouse epilepsy models. Epilepsia. https://doi.org/10.1111/epi.18037

Vancouver

Pérez-Pérez D, Monío-Baca C, von Rüden EL, Buchecker V, Wagner A, Schönhoff K, et al. Preclinical efficacy profiles of the sigma‐1 modulator E1R and of fenfluramine in two chronic mouse epilepsy models. Epilepsia. 2024. doi:10.1111/epi.18037

BibTeX
@article{PrezPrez2024,
  author = {Pérez-Pérez, Daniel and Monío-Baca, Cristina and von Rüden, Eva-Lotta and Buchecker, Verena and Wagner, Amelie and Schönhoff, Katharina and Zvejniece, Liga and Klimpel, Dennis and Potschka, Heidrun},
  title = {Preclinical efficacy profiles of the sigma‐1 modulator E1R and of fenfluramine in two chronic mouse epilepsy models},
  journal = {Epilepsia},
  year = {2024},
  doi = {10.1111/epi.18037}
}
Kostenlos starten →